辛伐他汀对ACS患者血清MMP-9及TIMP-1影响的临床分析被引量：1

下载PDF

导出

摘要目的观察辛伐他汀对急性冠状动脉综合征(ACS)患者血清基质金属蛋白酶-9(MMP-9)及其组织抑制因子-1(TIMP-1)的影响。方法采用酶联免疫法测定ACS患者(38例)稳定性心绞痛(SAP)患者(32例)血清TIMP-1及MMP-9浓度,在辛伐他汀治疗后复查TIMP-1及MMP-9的变化,并与健康对照组(20例)比较。结果 ACS组血清MMP-9显著高于SAP组及对照组(均P<0.05),而TIMP-1显著低于SAP组及对照组(均P<0.05),SAP组MMP-9显著高于对照组(P<0.05),SAP组TIMP-1与对照组之间差异(P>0.05);辛伐他汀治疗4周后ACS患者血清MMP-9水平下降,TIMP-1水平上升,与治疗前比较差异具有显著性(均P<0.05),SAP组MMP-9与治疗前比较差异具有显著性(P<0.05),而SAP组TIMP-1无明显改变(P>0.05)。结论 ACS患者MMP-9升高及TIMP-1下降,可能与ACS发病机制密切相关,辛伐他汀能降低ACS患者MMP-9及升高TIMP-1,对于ACS的临床治疗有着重要的意义。

作者史冬

机构地区河南省南阳市第三人民医院内科

出处《中国现代药物应用》 2010年第18期129-130,共2页 Chinese Journal of Modern Drug Application

关键词急性冠状动脉综合征基质金属蛋白酶辛伐他汀

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献6

1Foley M.Inflammation in acute coronary syndromes.Heart,2002,87:201-204.
2Shah PK,Falk Badinom J J,et al.Human monocyte derived maerophages induce collagen breaddown in fibrous caps of atheroscerotic plaque:potential role of matrix degrading metalloproteinases and inplications for plaque rupture.Circulation,1995,92(8):1565-1569.
3李玉成.辛伐他汀对急性心肌梗死早期血脂和炎症因子的影响[J].中国现代药物应用,2009,3(15):146-147. 被引量：6
4Kalela A,Koivu T A,Sisto T,et al.Serum matrix metaloproteitmse-9 concentration in angiographically assessed coronary artery disease.Stand J Clin lab invest,2002,62(2):337-342.
5Blankenberg S,Ruppreeht HJ,Pokier O,et al.Piasma concentrations and genetic variation of matrix metalloprotelnase 9 and prognosis of paients with cardiovascular discase.Circulation,2003,107(5):1579-1585.
6曹雅旻,胡大一.辛伐他汀对巨噬细胞基质金属蛋白酶-2、9表达及分泌的影响[J].中华心血管病杂志,2004,32(7):640-642. 被引量：21

二级参考文献10

1Yudkin JS,Kumari M,Humphries SE,et al.Inflammation,obesity,stressand coronary heart disease is interleukin-6 the link? Atherosclerosis,1999,148(2):209-214.
2Downs JR,Clearfied M,Weis S,et al.Primary prevention of acute coronary events with lovastatin in men and wemen with average1998 cholesterol levels:results of AFCAPS/TexCAPS.JAMA,279:I615-1622.
3Roseneoa RS,Tangney C.Antiatherothrombotie properties of statins:implications for eardialvascular event reduction.JAMA,1998,279:1643-1650.
4Girona J,La Ville AE, Sola R,et al. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol, 1999, 83:846-851.
5Ogawa K, Funaba M, Mathews LS, et al. Activin A stimulates type IV collagenase (matrix metalloproteinase-2) production in mouse peritoneal macrophages. J Immunol, 2000, 165: 2997-3003.
6Kim MH, Kitson RP, Albertsson P,et al. Secreted and membrane-associated matrix metalloproteinases of IL-2-activated NK cells and their inhibtors. J Immunol, 2000, 164:5883-5889.
7Gtte ET, Inge TC,Flemming SJ. Structural differences of metalloproteinases homology modeling and energy minimization of enzyme-substrate complexes. J Biomolecul Struc Dynami, 2000, 17:739-1102.
8Moreno MJ, Falk E, Palacios IF, et al. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation, 1994, 90:775-778.
9关瑜,张梦玺,袁洪,杨季,王建刚.内皮素及细胞因子在冠心病发病中的意义[J].湖南医科大学学报,1998,23(6):569-571. 被引量：12
10高润霖.他汀类药物在急性冠状动脉综合征的应用[J].中华心血管病杂志,2003,31(8):635-636. 被引量：150